In the Japanese pharmaceutical industry, there were 19 M&A deals announced in Q2 2023, worth a total value of $302.1m, according to GlobalData’s Deals Database. The $183.8m acquisition of daiichi sankyo espha by qol was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in Japan increased by 233% in Q2 2023 compared with the previous quarter’s total of $90.8m and fell by 44% as compared to Q2 2022. Related deal volume increased by 6% in Q2 2023 versus the previous quarter and was 171% higher than in Q2 2022.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.